Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review

Rheumatology International

Volumn 35, Issue 7, 2015, Pages 1193-1210

  Ferriols Lisart, Rafael ^a   Ferriols Lisart, Francisco ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Adalimumab; Dosing patterns; Etanercept; Infliximab; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR;

ARTICLE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; EMBASE; HUMAN; MEDLINE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; WEB OF SCIENCE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CHI SQUARE DISTRIBUTION; DOSE CALCULATION; IMMUNOLOGY; META ANALYSIS; ODDS RATIO; RISK FACTOR; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CHI-SQUARE DISTRIBUTION; DRUG DOSAGE CALCULATIONS; HUMANS; ODDS RATIO; RISK FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929834401     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-015-3222-4     Document Type: Article

References (72)

1. Aaltonen K, Virkki LM, Malmivaara A et al (2012) Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. Plos One. 7(1):e30275
2. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord [Internet]. 2008; 9: 52; doi:10.1186/1471-2474-9-52 (cited 2014 Dec 20)
3. Weins A, Venson R, Correr CJ et al (2010) Meta-analysis of the efficacy and safety of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 30(4):339–353
4. Felson DT, Smolen JS, Wells G et al (2011) American college of rheumatology/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404–413
5. Anderson J, Caplan L, Yazdany J et al (2012) Rheumatoid arthritis disease activity measures: American college of rheumatology recommendations for use in clinical practice. Arthritis Care Res 64(5):640–647
6. Tornero J, Sanmartí R, Rodriguez V et al (2010) Actualización del documento de consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide. Reumatología Clin. 6(1):23–36
7. Vincent FB, Morand EF, Murphy K et al (2013) Antidrug antibodies (ADAb) to tumor necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 72(2):165–178
8. Garces S, Demengeot J, Benito-García E (2013) The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72(12):1947–1955
9. Nair K, Tang B, Van Den Bos J et al (2009) Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and medicare populations. Curr Med Res Opin 25(2):303–314
10. Harrison D, Huang X, Globe D (2010) Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am J Health Syst Pharm. 67(15):1281–1287
11. Ariza-Ariza R, Navarro-Sarabia F, Hernández-Cruz B et al (2007) Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology. 46(3):529–532
12. Kievit W, Fransen J, Oerlemans A et al (2007) The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomized controlled trials and clinical practice. Ann Rheum Dis 66(11):1473–1478
13. Liberati A, Altman D, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):e1–e34
14. Stroup D, Berlin J, Morton S et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008–2012
15. Higgins P, Green S. Cochrane Handbook for systematic reviews of interventions version 5.1.0, the cochrane collaboration, 2011. Available: http://handbook.cochrane.org/ (cited: 2014 Dec 22)
16. Higgins J, Thompson S, Deeks J et al (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560
17. Berger A, Edelsberg J, Li T et al (2005) Dose intensification with infliximab in patients with rheumatoid arthritis. Rheumatology 39(12):2021–2025
18. Ollendorf D, Klingman D, Hazard E et al (2009) Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther 31(4):825–835
19. Ollendorf D, Massarotti E, Birbara C et al (2005) Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm. 11(5):383–393
20. Vollenhoven R, Brannemark S, Klareskog L (2004) Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 63(4):426–430
21. Escudero-Vilaplana V, Ramírez-Herraiz E, Trovato-López N et al (2012) Influence on effectiveness of early treatment with anti-TNF therapy in rheumatoid arthritis. J Pharm Pharmaceut Sci. 15(2):355–360
22. Kievit W, Adang E, Fransen J et al (2008) The effectiveness and medication costs of three anti-tumour necrosis factor α agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 67(9):1229–1234
23. Favalli EG, Marchesoni A, Colombo GL, Sinigaglia L (2008) Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy. Clin Exp Rheumatol 26(1):45–51
24. Kristensen LE, Geborek P, Saxne T (2009) Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the south Swedish arthritis treatment group register. Rheumatology 48(3):243–245
25. Huang X, Gu NY, Fox KM et al (2010) Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. Curr Med Res Opin 26(7):1637–1645
26. Bolge SC, Carter CT, Mueller CS et al (2012) Comparative multidatabase analysis of dosing patterns and infusion intervals for the first 12 infliximab infusions in patients with rheumatoid arthritis. Clin Ther 34(12):2286–2292
27. Moots RJ, Haraoui B, Matucci-Cerinic M et al (2011) Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol 29(1):26–34
28. Scheinberg M, Goldenberg Feldman D P et al (2008) Retrospective study evaluating dose standards for infliximab in patients with rheumatoid arthritis at Hospital Israelita Albert Einstein, São Paulo, Brazil. Clin Rheumatol. 27(8):1049–1052
29. Ogale S, Hitraya E, Henk H J. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord. [Internet]. 2011; 12: 204; doi: 10.1186/1471-2474-12-204(cited: 2014 Dec 15)
30. Punzi L, Matucci-Cerinic M, Cantini F et al (2011) Treatment patterns of anti-TNF agents in Italy: an observational study. Reumatismo. 63(1):18–28
31. Fisher MD, Watson C, Fox KM et al (2013) Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population. Curr Med Res Opin 29(5):561–568
32. Ramírez-Herráiz E, Escudero-Vilaplana V, Alañón-Plaza E et al (2013) Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice. Clin Exp Rheumatol 31(4):559–565
33. Schabert VF, Bruce B, Ferrufino CF et al (2012) Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study. Curr Med Res Opin 28(4):569–580
34. Yazici Y, Krasnokutsky S, Barnes JP et al (2013) Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol 36(5):907–913
35. Blume SW, Fox KM, Joseph G et al (2013) Tumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management setting. Adv Ther. 30(5):517–527
36. Inciarte-Mundo J, Hernández MV, Rosario V et al (2014) Reducción de dosis de terapias biológicas en enfermedades reumáticas: análisis descriptivo de 153 pacientes en condiciones de práctica clínica. Reumatol Clin. 10(1):10–16
37. Bonafede MK, Gandra SR, Fox KM et al (2012) Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. J Med Econ. 15(4):1–9
38. Blom M, Kievit W, Kuper HH et al (2010) Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care Res (Hoboken). 62(9):1335–1341
39. Wu E, Chen L, Birnbaum H et al (2008) Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin 24(8):2229–2240
40. Joyce A, Gandra S, Fox K et al (2014) National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans. J Med Econ. 17(1):1–10
41. Abarca J, Malone D, Armstrong E et al (2004) Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit. J Manag Care Pharm. 10(6):538–542
42. Etemad L, Yu B, Wanke A (2005) Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface. 18(4):21–27
43. George D, Kadlubek P, Batra D, et al. Infliximab dose and charge escalation patterns in managed care. Manag Care Interface. 2004; Suppl A:5–8
44. Gilbert T Jr, Smith D, Ollendorf D (2004) Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord. 5(1):36
45. Harley CR, Frytak JR, Tandon N (2003) Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care. 9(suppl.6):s136–s143
46. Stern R, Wolfe F (2004) Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 31(8):1538–1545
47. Agarwal SK, Maier AL, Chibnik LB et al (2005) Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 53(6):872–878
48. Van Vollenhoven RF, Klareskog L (2007) Infliximab dosage and infusión frequency in clinical practice: experience in the Stockholm biologics registry STURE. Scand J Rheumatol 36(6):418–423
49. Daniel G, McNeely B, Huang X, et al. Dose patterns and health plan costs among RA patients treated with tumor necrosis factor antagonists. [abstract]. American College of Rheumatology. Annual Scientific Meeting 2008. Available: https://acr.confex.com/acr/2008/webprogram/Paper3442.html
50. Khanna D, Cyhaniuk A, Bedenbaugh A (2011) Use of TNF-inhibitors in the US: utilisation patterns and dose escalation from a representative US rheumatoid arthritis (RA) population. [abstract]. Ann Rheum Dis. 70(suppl.3):97
51. Tang B, Greenburg J, Reed G et al (2009) Analysis of infliximab dose and interval patterns in patients with rheumatoid arthritis in the consortium of rheumatology researchers of North America (CORRONA) registry. [abstract]. Ann Rheum Dis 68(Suppl. 3):231
52. Engel-Nitz N, Huang X, Globe D et al (2007) Dosing patterns and costs of adalimumab, etanercept, and infliximab among patients with rheumatoid arthritis. [abstract]. Ann Rheum Dis. 66(suppl II):260
53. Zhang J, Xie F, Delzell E, et al. Persistent use of biologic therapies at lower than recommended dosing among rheumatoid arthritis patients enrolled in the US medicare program. [abstract]. American College of Rheumatology. Annual Scientific Meeting 2013. Available: https://ww2.rheumatology.org/apps/MyAnnualMeeting/Abstract/34866
54. Hanna B, Shah A. Drug survival and long-term dose comparison of etanercept and infliximab in rheumatoid arthritis patients. [abstract]. American College of Rheumatology. Annual Scientific Meeting 2011. Available: https://acr.confex.com/acr/2011/webprogram/Paper20448.html
55. Darkow T, Chastek B, Rosenblatt L et al (2011) Dose escalation among rheumatoid arthritis patients treated with infliximab or abatacept: comparison in claims Data. [abstract]. Arthritis Rheum. 63(suppl.10):1221
56. Tang B, Rahman R, Waters HC et al (2008) Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 30(7):1375–1384
57. Hetland M, Christensen U, Tarp U et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab results from eight years of surveillance of clinical practice in the nationwide Danish DANIBIO registry. Arthritis Rheum 62(1):22–32
58. Marchesoni A, Zaccara E, Gorla R et al (2009) TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 1173:837–846
59. Ward M (2010) Medicare reimbursement and the use of biologic agents: incentives, access, the public good, and optimal care. Arthritis Care Res (Hoboken) 62(3):293–295
60. DeWitt E, Glick H, Albert D et al (2006) Medicare coverage of tumor necrosis factor α inhibitors as an influence on physicians’ prescribing behavior. Arch Intern Med. 166(13):57–63
61. Wolbink GJ, Vis M, Lems W et al (2006) Development of antiinfliximab antibodies and relationship to clinical response in patient with rheumatoid arthritis. Arthritis Rheum 54(3):711–715
62. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al (2007) Clinical reponse to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66(7):921–926
63. Pascual-Salcedo D, Plasencia C, Ramiro S et al (2011) Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 50(8):1445–1452
64. Korswagen LA, Bartelds GM, Krieckaert CL et al (2011) Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum 63(4):877–883
65. Singh J, Christensen R, Wells G et al (2009) A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane review. CMAJ 181(11):787–796
66. Curtis J, Jain A, Askling J et al (2010) A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 40(1):2–14
67. Wolfe F, Michaud K (2005) Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness. Rheumatology 44(suppl.4):iv8–iv22
68. Schabert V, Gandra C, Goodman S et al (2012) Annual costs of tumor necrosis factor inhibitors using real-world data in commercially insured population in the United States. J Med Econ. 15(2):264–275
69. Sanderson S, Tatt I, Higgins J et al (2007) Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 36(3):666–676
70. Dreyer N, Velentgas P, Westrich K et al (2014) The GRACE checklist for rating the quality of observational studies of comparative effectiveness: a tale of hope and caution. J Manag Care Pharm 20(3):301–308
71. Zandvliet M, Bezooijen J, Bos M et al (2013) Monitoring antigen-specific biologics: current knowledge and future prospects. Ther Drug Monit 35(5):588–594
72. Azevedo V, Galli N, Kleinfelder A, et al. Etanercept biosimilar. Rheumatol Int [Internet]. 2014. doi:10.1007/s00296-014-3080-5 (cited: 2014 Dec 20)